-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$9.00198.01% Upside
Trevi Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Trevi Therapeutics, Inc.?
Trevi Therapeutics, Inc. has been rated by research analysts at B.Riley Financial, Oppenheimer in the past 90 days.